PURPOSE: Following two cases of neutralizing antibodies to epoetin alfa in an investigational clinical study, a small number of individual syringes of two drug product batches were found to contain unusually high levels of aggregation at the end of the clinical trial. METHODS: We undertook an extensive analytical approach to determine the root-cause of the increased aggregation in the affected batches. RESULTS: Soluble tungsten was found in the syringes, most likely derived from the pins used to manufacture the syringes. Spiking of epoetin alfa with sodium polytungstate or an extract of tungsten pins used to manufacture the syringes induced the formation of aggregates, both dimers that appeared to be covalently linked by disulphide bonds as well as higher-order aggregates. Sodium polytungstate had also a strong denaturing effect on the protein. CONCLUSIONS: We propose tungsten-mediated unfolding and aggregation of epoetin alfa in pre-filled syringes as a potential root cause for increased immunogenicity. This finding may be more broadly applicable to this and other classes of therapeutic proteins.
PURPOSE: Following two cases of neutralizing antibodies to epoetin alfa in an investigational clinical study, a small number of individual syringes of two drug product batches were found to contain unusually high levels of aggregation at the end of the clinical trial. METHODS: We undertook an extensive analytical approach to determine the root-cause of the increased aggregation in the affected batches. RESULTS: Soluble tungsten was found in the syringes, most likely derived from the pins used to manufacture the syringes. Spiking of epoetin alfa with sodium polytungstate or an extract of tungsten pins used to manufacture the syringes induced the formation of aggregates, both dimers that appeared to be covalently linked by disulphide bonds as well as higher-order aggregates. Sodium polytungstate had also a strong denaturing effect on the protein. CONCLUSIONS: We propose tungsten-mediated unfolding and aggregation of epoetin alfa in pre-filled syringes as a potential root cause for increased immunogenicity. This finding may be more broadly applicable to this and other classes of therapeutic proteins.
Authors: Abraham Jacob; Kanwaljit Sandhu; Johann Nicholas; Helen Jones; Jonathan Odum; Paul Rylance; Paul Carmichael; Maurice Jackson; Sunil Handa; Alan Macwhannell; Supratik Basu; Faisal Wahid; Nicole Casadevall; Ghulam Mufti; Iain Macdougall Journal: Nephrol Dial Transplant Date: 2006-07-20 Impact factor: 5.992
Authors: Charles L Bennett; Stefano Luminari; Allen R Nissenson; Martin S Tallman; Stephen A Klinge; Norene McWilliams; June M McKoy; Benjamin Kim; E Allison Lyons; Steve M Trifilio; Dennis W Raisch; Andrew M Evens; Timothy M Kuzel; Glen T Schumock; Steven M Belknap; Francesco Locatelli; Jerôme Rossert; Nicole Casadevall Journal: N Engl J Med Date: 2004-09-30 Impact factor: 91.245
Authors: John den Engelsman; Patrick Garidel; Ronald Smulders; Hans Koll; Bryan Smith; Stefan Bassarab; Andreas Seidl; Otmar Hainzl; Wim Jiskoot Journal: Pharm Res Date: 2010-10-23 Impact factor: 4.200
Authors: Charles L Bennett; Brian Chen; Terhi Hermanson; Michael D Wyatt; Richard M Schulz; Peter Georgantopoulos; Samuel Kessler; Dennis W Raisch; Zaina P Qureshi; Z Kevin Lu; Bryan L Love; Virginia Noxon; Laura Bobolts; Melissa Armitage; John Bian; Paul Ray; Richard J Ablin; William J Hrushesky; Iain C Macdougall; Oliver Sartor; James O Armitage Journal: Lancet Oncol Date: 2014-11-24 Impact factor: 41.316